跳至主要内容
临床试验/NCT05394246
NCT05394246招募中不适用

Intraoperative Liver Tumor Imaging Using Fluorescent-labeled Human IgG

Chinese Academy of Sciences1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2022年5月20日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
招募中
入组人数
60
试验地点
1
主要终点
Tumor imaging precision

研究概览

简要总结

This study is to evaluate whether intraoperative fluorescence imaging using fluorescent-labeled IgG probe (FluoAB) can help distinguish the tumor and the liver cirrhosis (or the liver parenchyma).

The main purposes of this study include:

  • To validate the safety and effectiveness of using FluoAB in hepatic surgery.
  • To raise the surgical precision with guidance by FluoAB fluorescence imaging.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients who have been diagnosed with liver tumor.
  • Planned to receive hepatectomy.
  • Liver function Child-Pugh A/B.
  • The expected lifetime is longer than 6 months.
  • Approved to sign the informed consent.

排除标准

  • Enrolled in other trials in the past 3 months.
  • Metastatic lesions were found.
  • Undesirable function of heart, lung, kidney, or any other organs.
  • Unable to tolerate a hepatectomy.
  • The researchers considered inappropriate to be included.

研究组 & 干预措施

FluoAB intraoperative fluorescence imaging

Experimental

The patients will receive an injection of FluoAB. Surgery will be performed with guidance by FluoAB fluorescence imaging.

干预措施: FluoAB (Drug)

结局指标

主要结局

Tumor imaging precision

时间窗: Update with an average of 2 weeks.

Sensitivity and specificity of hepatic malignancy detection by fluoAB intraoperative imaging.

Tumor lesions

时间窗: Immediately after the hepatic surgery.

Numbers of intraoperatively detected tumor lesions.

次要结局

未报告次要终点

研究者

申办方类型
Other Gov
责任方
Principal Investigator
主要研究者

Zeyu Zhang, PHD

Principal Investigator

Chinese Academy of Sciences

研究点 (1)

Loading locations...

相似试验